A 48-year-old male with MSyn after treatment with the immune checkpoint inhibitor pembrolizumab for malignant melanoma, positive for anti-Yo and anti-titin antibodies, was presented to our unit with severe respiratory failure, heart failure (due to myositis, also caused by the pembrolizumab treatment), and generalized muscle weakness. This evidence concerns the gene CDR2 and melanoma.